Sabra Health Care REIT A Buy, As Q1 Results Show Portfolio Growth

Sabra Health Care REIT is rated a buy, reflecting portfolio growth, reasonable valuation, and robust geographic diversification. SBRA demonstrates strong revenue and NOI growth but faces declining EBITDA margins and flat long-term dividend growth, tempering its income appeal. The REIT maintains an investment-grade balance sheet, modest debt-to-equity, low operator concentration, and adequate AFFO dividend coverage with a 5.6% yield.